Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) CAO Kristen Marie Williams sold 3,461 shares of the stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $36.75, for a total value of $127,191.75. Following the transaction, the chief accounting officer now directly owns 21,312 shares in the company, valued at approximately $783,216. The transaction was disclosed in a filing with the SEC, which is available at this link.

Kristen Marie Williams also recently made the following trade(s):

  • On Monday, June 5th, Kristen Marie Williams sold 1,877 shares of Pacira Pharmaceuticals stock. The stock was sold at an average price of $43.32, for a total value of $81,311.64.

Shares of Pacira Pharmaceuticals, Inc. (PCRX) traded down 2.96% during mid-day trading on Thursday, hitting $36.05. The stock had a trading volume of 634,079 shares. The company’s market cap is $1.45 billion. Pacira Pharmaceuticals, Inc. has a 52-week low of $29.95 and a 52-week high of $58.95. The stock has a 50 day moving average price of $43.76 and a 200-day moving average price of $45.31.

Pacira Pharmaceuticals (NASDAQ:PCRX) last released its quarterly earnings results on Wednesday, August 2nd. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by $0.06. The firm had revenue of $70.90 million during the quarter, compared to analyst estimates of $73.37 million. Pacira Pharmaceuticals had a negative return on equity of 12.44% and a negative net margin of 23.36%. The business’s revenue was up 1.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.21 EPS. On average, equities analysts expect that Pacira Pharmaceuticals, Inc. will post ($0.12) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Pacira Pharmaceuticals, Inc. (PCRX) CAO Sells $127,191.75 in Stock” was published by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/08/17/pacira-pharmaceuticals-inc-pcrx-cao-sells-127191-75-in-stock.html.

A number of equities research analysts recently weighed in on the company. Royal Bank Of Canada set a $58.00 price objective on Pacira Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, May 15th. Canaccord Genuity reaffirmed a “buy” rating and set a $60.00 price objective on shares of Pacira Pharmaceuticals in a research report on Monday, May 15th. Cowen and Company reaffirmed a “hold” rating on shares of Pacira Pharmaceuticals in a research report on Friday, July 14th. Wedbush reaffirmed an “outperform” rating and set a $87.00 price objective on shares of Pacira Pharmaceuticals in a research report on Wednesday, July 19th. Finally, Zacks Investment Research cut Pacira Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, May 2nd. Three analysts have rated the stock with a sell rating, six have given a hold rating and eight have issued a buy rating to the company. Pacira Pharmaceuticals presently has an average rating of “Hold” and an average target price of $54.50.

Several large investors have recently added to or reduced their stakes in PCRX. Benjamin F. Edwards & Company Inc. boosted its stake in Pacira Pharmaceuticals by 85.6% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 2,491 shares of the company’s stock worth $114,000 after buying an additional 1,149 shares in the last quarter. Oppenheimer Asset Management Inc. bought a new stake in shares of Pacira Pharmaceuticals during the second quarter worth approximately $114,000. FNY Partners Fund LP bought a new stake in shares of Pacira Pharmaceuticals during the first quarter worth approximately $136,000. Ameritas Investment Partners Inc. bought a new stake in shares of Pacira Pharmaceuticals during the first quarter worth approximately $144,000. Finally, Cubist Systematic Strategies LLC boosted its stake in shares of Pacira Pharmaceuticals by 121.5% in the second quarter. Cubist Systematic Strategies LLC now owns 3,194 shares of the company’s stock worth $152,000 after buying an additional 1,752 shares during the period.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Insider Buying and Selling by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.